Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714
NCT03759522Phase 1Recruiting
- Sponsor
- University of Alabama at Birmingham
- Start
- Feb 2019
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of DPA-714 in fibromyalgia (FM), myalgic encephalomyelitis chronic fatigue syndrome (ME/CFS) and multiple sclerosis (MS) (4 arms), sponsored by University of Alabama at Birmingham. Primary endpoint: Neuroinflammation measured with [F-18]DPA-714-PET/MRI at 3 years. Started Feb 2019; status: recruiting.
02
Drugs
DPA-714
03
Conditions
fibromyalgia (FM)myalgic encephalomyelitis chronic fatigue syndrome (ME/CFS)multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT03759522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03759522.